nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—L-Phenylalanine—Melphalan—peripheral nervous system neoplasm	0.673	1	CrCrCtD
Phenylpropanolamine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0214	0.457	CbGbCtD
Phenylpropanolamine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0171	0.365	CbGbCtD
Phenylpropanolamine—Renal tubular necrosis—Tretinoin—peripheral nervous system neoplasm	0.00857	0.0423	CcSEcCtD
Phenylpropanolamine—Renal tubular necrosis—Isotretinoin—peripheral nervous system neoplasm	0.00857	0.0423	CcSEcCtD
Phenylpropanolamine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00839	0.179	CbGbCtD
Phenylpropanolamine—Renal tubular necrosis—Alitretinoin—peripheral nervous system neoplasm	0.00649	0.0321	CcSEcCtD
Phenylpropanolamine—L-Phenylalanine—TH—peripheral nervous system neoplasm	0.0037	0.645	CrCbGaD
Phenylpropanolamine—Hepatocellular injury—Tretinoin—peripheral nervous system neoplasm	0.00306	0.0151	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Isotretinoin—peripheral nervous system neoplasm	0.00306	0.0151	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Melphalan—peripheral nervous system neoplasm	0.00302	0.0149	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Tretinoin—peripheral nervous system neoplasm	0.00263	0.013	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Isotretinoin—peripheral nervous system neoplasm	0.00263	0.013	CcSEcCtD
Phenylpropanolamine—Liver injury—Cisplatin—peripheral nervous system neoplasm	0.00235	0.0116	CcSEcCtD
Phenylpropanolamine—DRD1—nerve—peripheral nervous system neoplasm	0.00233	0.112	CbGeAlD
Phenylpropanolamine—Hepatocellular injury—Alitretinoin—peripheral nervous system neoplasm	0.00232	0.0115	CcSEcCtD
Phenylpropanolamine—DRD1—ganglion—peripheral nervous system neoplasm	0.0023	0.111	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Tretinoin—peripheral nervous system neoplasm	0.00217	0.0107	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Isotretinoin—peripheral nervous system neoplasm	0.00217	0.0107	CcSEcCtD
Phenylpropanolamine—Irritability—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.0105	CcSEcCtD
Phenylpropanolamine—Irritability—Tretinoin—peripheral nervous system neoplasm	0.00212	0.0105	CcSEcCtD
Phenylpropanolamine—Ephedrine—BCHE—peripheral nervous system neoplasm	0.00204	0.356	CrCbGaD
Phenylpropanolamine—Euphoric mood—Alitretinoin—peripheral nervous system neoplasm	0.00199	0.00984	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Cisplatin—peripheral nervous system neoplasm	0.00198	0.00976	CcSEcCtD
Phenylpropanolamine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00187	0.09	CbGeAlD
Phenylpropanolamine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.00185	0.0888	CbGeAlD
Phenylpropanolamine—Drowsiness—Isotretinoin—peripheral nervous system neoplasm	0.00171	0.00845	CcSEcCtD
Phenylpropanolamine—Drowsiness—Tretinoin—peripheral nervous system neoplasm	0.00171	0.00845	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Alitretinoin—peripheral nervous system neoplasm	0.00164	0.00812	CcSEcCtD
Phenylpropanolamine—Irritability—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00793	CcSEcCtD
Phenylpropanolamine—Urinary retention—Vincristine—peripheral nervous system neoplasm	0.00154	0.00762	CcSEcCtD
Phenylpropanolamine—Hallucination—Tretinoin—peripheral nervous system neoplasm	0.00153	0.00755	CcSEcCtD
Phenylpropanolamine—Hallucination—Isotretinoin—peripheral nervous system neoplasm	0.00153	0.00755	CcSEcCtD
Phenylpropanolamine—Ataxia—Vincristine—peripheral nervous system neoplasm	0.00153	0.00753	CcSEcCtD
Phenylpropanolamine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00151	0.0726	CbGeAlD
Phenylpropanolamine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00149	0.0717	CbGeAlD
Phenylpropanolamine—Flushing—Tretinoin—peripheral nervous system neoplasm	0.00143	0.00704	CcSEcCtD
Phenylpropanolamine—Flushing—Isotretinoin—peripheral nervous system neoplasm	0.00143	0.00704	CcSEcCtD
Phenylpropanolamine—Flushing—Melphalan—peripheral nervous system neoplasm	0.00141	0.00695	CcSEcCtD
Phenylpropanolamine—MAOA—nerve—peripheral nervous system neoplasm	0.00139	0.0669	CbGeAlD
Phenylpropanolamine—MAOA—ganglion—peripheral nervous system neoplasm	0.00138	0.066	CbGeAlD
Phenylpropanolamine—Arrhythmia—Tretinoin—peripheral nervous system neoplasm	0.00137	0.00678	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Isotretinoin—peripheral nervous system neoplasm	0.00137	0.00678	CcSEcCtD
Phenylpropanolamine—Irritability—Cisplatin—peripheral nervous system neoplasm	0.00137	0.00676	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Melphalan—peripheral nervous system neoplasm	0.00136	0.00669	CcSEcCtD
Phenylpropanolamine—Tension—Isotretinoin—peripheral nervous system neoplasm	0.00131	0.00648	CcSEcCtD
Phenylpropanolamine—Tension—Tretinoin—peripheral nervous system neoplasm	0.00131	0.00648	CcSEcCtD
Phenylpropanolamine—Nervousness—Tretinoin—peripheral nervous system neoplasm	0.0013	0.00642	CcSEcCtD
Phenylpropanolamine—Nervousness—Isotretinoin—peripheral nervous system neoplasm	0.0013	0.00642	CcSEcCtD
Phenylpropanolamine—Drowsiness—Alitretinoin—peripheral nervous system neoplasm	0.0013	0.00641	CcSEcCtD
Phenylpropanolamine—Vision blurred—Tretinoin—peripheral nervous system neoplasm	0.00126	0.00622	CcSEcCtD
Phenylpropanolamine—Vision blurred—Isotretinoin—peripheral nervous system neoplasm	0.00126	0.00622	CcSEcCtD
Phenylpropanolamine—Tremor—Tretinoin—peripheral nervous system neoplasm	0.00125	0.00619	CcSEcCtD
Phenylpropanolamine—Tremor—Isotretinoin—peripheral nervous system neoplasm	0.00125	0.00619	CcSEcCtD
Phenylpropanolamine—Agitation—Isotretinoin—peripheral nervous system neoplasm	0.00123	0.00607	CcSEcCtD
Phenylpropanolamine—Agitation—Tretinoin—peripheral nervous system neoplasm	0.00123	0.00607	CcSEcCtD
Phenylpropanolamine—Liver injury—Epirubicin—peripheral nervous system neoplasm	0.00121	0.00595	CcSEcCtD
Phenylpropanolamine—Flushing—Dactinomycin—peripheral nervous system neoplasm	0.00117	0.00576	CcSEcCtD
Phenylpropanolamine—Hallucination—Alitretinoin—peripheral nervous system neoplasm	0.00116	0.00572	CcSEcCtD
Phenylpropanolamine—Anxiety—Isotretinoin—peripheral nervous system neoplasm	0.00114	0.0056	CcSEcCtD
Phenylpropanolamine—Anxiety—Tretinoin—peripheral nervous system neoplasm	0.00114	0.0056	CcSEcCtD
Phenylpropanolamine—Hallucination—Vincristine—peripheral nervous system neoplasm	0.00112	0.00551	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—peripheral nervous system neoplasm	0.00112	0.00551	CcSEcCtD
Phenylpropanolamine—Confusional state—Tretinoin—peripheral nervous system neoplasm	0.0011	0.00544	CcSEcCtD
Phenylpropanolamine—Confusional state—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.00544	CcSEcCtD
Phenylpropanolamine—Flushing—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00534	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Epirubicin—peripheral nervous system neoplasm	0.00108	0.00533	CcSEcCtD
Phenylpropanolamine—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00107	0.00526	CcSEcCtD
Phenylpropanolamine—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00107	0.00526	CcSEcCtD
Phenylpropanolamine—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00105	0.00519	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00514	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Epirubicin—peripheral nervous system neoplasm	0.00103	0.0051	CcSEcCtD
Phenylpropanolamine—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.00102	0.00504	CcSEcCtD
Phenylpropanolamine—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.00102	0.00504	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Epirubicin—peripheral nervous system neoplasm	0.00101	0.00501	CcSEcCtD
Phenylpropanolamine—Hypotension—Melphalan—peripheral nervous system neoplasm	0.00101	0.00497	CcSEcCtD
Phenylpropanolamine—DRD1—brainstem—peripheral nervous system neoplasm	0.001	0.0481	CbGeAlD
Phenylpropanolamine—Dyskinesia—Doxorubicin—peripheral nervous system neoplasm	0.000999	0.00493	CcSEcCtD
Phenylpropanolamine—Tension—Alitretinoin—peripheral nervous system neoplasm	0.000995	0.00491	CcSEcCtD
Phenylpropanolamine—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.000988	0.00488	CcSEcCtD
Phenylpropanolamine—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.000988	0.00488	CcSEcCtD
Phenylpropanolamine—Nervousness—Alitretinoin—peripheral nervous system neoplasm	0.000985	0.00486	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.000981	0.00484	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.000973	0.00481	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.000973	0.00481	CcSEcCtD
Phenylpropanolamine—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.000971	0.00479	CcSEcCtD
Phenylpropanolamine—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.000971	0.00479	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.000961	0.00474	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000956	0.00472	CcSEcCtD
Phenylpropanolamine—Vision blurred—Alitretinoin—peripheral nervous system neoplasm	0.000956	0.00472	CcSEcCtD
Phenylpropanolamine—Tremor—Alitretinoin—peripheral nervous system neoplasm	0.00095	0.00469	CcSEcCtD
Phenylpropanolamine—Constipation—Topotecan—peripheral nervous system neoplasm	0.000941	0.00465	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—peripheral nervous system neoplasm	0.000939	0.00464	CcSEcCtD
Phenylpropanolamine—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000934	0.00461	CcSEcCtD
Phenylpropanolamine—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000934	0.00461	CcSEcCtD
Phenylpropanolamine—Agitation—Alitretinoin—peripheral nervous system neoplasm	0.000932	0.0046	CcSEcCtD
Phenylpropanolamine—Flushing—Cisplatin—peripheral nervous system neoplasm	0.000921	0.00455	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000907	0.00448	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.0009	0.00444	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.0009	0.00444	CcSEcCtD
Phenylpropanolamine—Agitation—Vincristine—peripheral nervous system neoplasm	0.000898	0.00443	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Cisplatin—peripheral nervous system neoplasm	0.000887	0.00438	CcSEcCtD
Phenylpropanolamine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.00086	0.00425	CcSEcCtD
Phenylpropanolamine—Flushing—Etoposide—peripheral nervous system neoplasm	0.000844	0.00417	CcSEcCtD
Phenylpropanolamine—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.000834	0.00412	CcSEcCtD
Phenylpropanolamine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000814	0.00402	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000811	0.004	CcSEcCtD
Phenylpropanolamine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000809	0.004	CcSEcCtD
Phenylpropanolamine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000808	0.00399	CcSEcCtD
Phenylpropanolamine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.000805	0.0386	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000804	0.00397	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000804	0.00397	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000794	0.00392	CcSEcCtD
Phenylpropanolamine—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000773	0.00382	CcSEcCtD
Phenylpropanolamine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000748	0.00369	CcSEcCtD
Phenylpropanolamine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000745	0.00368	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000738	0.00364	CcSEcCtD
Phenylpropanolamine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000736	0.00363	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000735	0.00363	CcSEcCtD
Phenylpropanolamine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000733	0.00362	CcSEcCtD
Phenylpropanolamine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000728	0.00359	CcSEcCtD
Phenylpropanolamine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000722	0.00356	CcSEcCtD
Phenylpropanolamine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000722	0.00356	CcSEcCtD
Phenylpropanolamine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000721	0.00356	CcSEcCtD
Phenylpropanolamine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000708	0.00349	CcSEcCtD
Phenylpropanolamine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.0007	0.00346	CcSEcCtD
Phenylpropanolamine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000694	0.00343	CcSEcCtD
Phenylpropanolamine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000694	0.00343	CcSEcCtD
Phenylpropanolamine—Rash—Topotecan—peripheral nervous system neoplasm	0.000694	0.00343	CcSEcCtD
Phenylpropanolamine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000693	0.00342	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—peripheral nervous system neoplasm	0.000693	0.00342	CcSEcCtD
Phenylpropanolamine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000688	0.0034	CcSEcCtD
Phenylpropanolamine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000688	0.0034	CcSEcCtD
Phenylpropanolamine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000688	0.0034	CcSEcCtD
Phenylpropanolamine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000688	0.0034	CcSEcCtD
Phenylpropanolamine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000688	0.0034	CcSEcCtD
Phenylpropanolamine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000685	0.00338	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000682	0.00337	CcSEcCtD
Phenylpropanolamine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000682	0.00337	CcSEcCtD
Phenylpropanolamine—Rash—Melphalan—peripheral nervous system neoplasm	0.00068	0.00335	CcSEcCtD
Phenylpropanolamine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000679	0.00335	CcSEcCtD
Phenylpropanolamine—MAOA—trigeminal ganglion—peripheral nervous system neoplasm	0.000676	0.0324	CbGeAlD
Phenylpropanolamine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000659	0.00325	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000658	0.00325	CcSEcCtD
Phenylpropanolamine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000654	0.00323	CcSEcCtD
Phenylpropanolamine—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000651	0.00322	CcSEcCtD
Phenylpropanolamine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.000649	0.0312	CbGeAlD
Phenylpropanolamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000649	0.0032	CcSEcCtD
Phenylpropanolamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000649	0.0032	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000641	0.00316	CcSEcCtD
Phenylpropanolamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.00064	0.00316	CcSEcCtD
Phenylpropanolamine—MAOA—parotid gland—peripheral nervous system neoplasm	0.000638	0.0306	CbGeAlD
Phenylpropanolamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00063	0.00311	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000629	0.0031	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00061	0.00301	CcSEcCtD
Phenylpropanolamine—ADRA1A—brainstem—peripheral nervous system neoplasm	0.000604	0.029	CbGeAlD
Phenylpropanolamine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000604	0.00298	CcSEcCtD
Phenylpropanolamine—MAOA—brainstem—peripheral nervous system neoplasm	0.000598	0.0287	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000587	0.0029	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000581	0.00287	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000576	0.00284	CcSEcCtD
Phenylpropanolamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000574	0.00283	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000568	0.0028	CcSEcCtD
Phenylpropanolamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000567	0.0028	CcSEcCtD
Phenylpropanolamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000563	0.00278	CcSEcCtD
Phenylpropanolamine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000552	0.00273	CcSEcCtD
Phenylpropanolamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000547	0.0027	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000532	0.00263	CcSEcCtD
Phenylpropanolamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00053	0.00262	CcSEcCtD
Phenylpropanolamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000527	0.0026	CcSEcCtD
Phenylpropanolamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000526	0.0026	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000525	0.00259	CcSEcCtD
Phenylpropanolamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000522	0.00258	CcSEcCtD
Phenylpropanolamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000521	0.00257	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000519	0.00256	CcSEcCtD
Phenylpropanolamine—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.000519	0.0249	CbGeAlD
Phenylpropanolamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000507	0.0025	CcSEcCtD
Phenylpropanolamine—Rash—Vincristine—peripheral nervous system neoplasm	0.000503	0.00248	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000502	0.00248	CcSEcCtD
Phenylpropanolamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000492	0.00243	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000476	0.00235	CcSEcCtD
Phenylpropanolamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000474	0.00234	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000473	0.00234	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000455	0.00225	CcSEcCtD
Phenylpropanolamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000448	0.00221	CcSEcCtD
Phenylpropanolamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000445	0.00219	CcSEcCtD
Phenylpropanolamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000444	0.00219	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000438	0.00216	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000435	0.00215	CcSEcCtD
Phenylpropanolamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000431	0.00213	CcSEcCtD
Phenylpropanolamine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000427	0.00211	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000421	0.00208	CcSEcCtD
Phenylpropanolamine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000419	0.00207	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000418	0.00206	CcSEcCtD
Phenylpropanolamine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000411	0.00203	CcSEcCtD
Phenylpropanolamine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000408	0.00201	CcSEcCtD
Phenylpropanolamine—Rash—Etoposide—peripheral nervous system neoplasm	0.000407	0.00201	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000407	0.00201	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.00199	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000399	0.00197	CcSEcCtD
Phenylpropanolamine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.000397	0.019	CbGeAlD
Phenylpropanolamine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.00191	CcSEcCtD
Phenylpropanolamine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000384	0.00189	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000377	0.00186	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000376	0.00186	CcSEcCtD
Phenylpropanolamine—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000365	0.0018	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000353	0.00174	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000348	0.00172	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000338	0.00167	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000338	0.00167	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000327	0.00162	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.00161	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000323	0.00159	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000322	0.00159	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000313	0.00155	CcSEcCtD
Phenylpropanolamine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00031	0.00153	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.0015	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.00147	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000298	0.00147	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.00147	CcSEcCtD
Phenylpropanolamine—ADRA1A—cerebellum—peripheral nervous system neoplasm	0.000298	0.0143	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—peripheral nervous system neoplasm	0.000295	0.0142	CbGeAlD
Phenylpropanolamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.00141	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.00136	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000267	0.00132	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.00122	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000239	0.00118	CcSEcCtD
Phenylpropanolamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00023	0.00114	CcSEcCtD
Phenylpropanolamine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000228	0.00113	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000228	0.00113	CcSEcCtD
Phenylpropanolamine—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.000226	0.0109	CbGeAlD
Phenylpropanolamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.00109	CcSEcCtD
Phenylpropanolamine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000215	0.00106	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.00105	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.00104	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.00104	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000982	CcSEcCtD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000163	0.00319	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000162	0.00317	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	0.000159	0.00311	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000158	0.0031	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000157	0.00308	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000151	0.00297	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000151	0.00297	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000138	0.0027	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000135	0.00265	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000132	0.00259	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000124	0.00243	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000123	0.00241	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.000121	0.00238	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000121	0.00238	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00012	0.00235	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000119	0.00233	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000118	0.00232	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000117	0.0023	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000117	0.0023	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000116	0.00228	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000115	0.00225	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000108	0.00211	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000106	0.00208	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000105	0.00207	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000105	0.00206	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000103	0.00203	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000102	0.00201	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000102	0.00201	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000101	0.00198	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.0001	0.00197	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	9.99e-05	0.00196	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	9.8e-05	0.00192	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	9.59e-05	0.00188	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	9.42e-05	0.00185	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—AMPK Signaling—TP53—peripheral nervous system neoplasm	9.38e-05	0.00184	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	9.36e-05	0.00184	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	9.3e-05	0.00183	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	9.22e-05	0.00181	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.16e-05	0.0018	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	9.07e-05	0.00178	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	8.98e-05	0.00176	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	8.91e-05	0.00175	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	8.79e-05	0.00172	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	8.71e-05	0.00171	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	8.7e-05	0.00171	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GNS—peripheral nervous system neoplasm	8.55e-05	0.00168	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.37e-05	0.00164	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	8.35e-05	0.00164	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.29e-05	0.00163	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	8.24e-05	0.00162	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	8.22e-05	0.00161	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NME1—peripheral nervous system neoplasm	8.2e-05	0.00161	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	8.16e-05	0.0016	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	8.1e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	8.09e-05	0.00159	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	8.06e-05	0.00158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	7.98e-05	0.00157	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—AMPK Signaling—AKT1—peripheral nervous system neoplasm	7.92e-05	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.91e-05	0.00155	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—COX2—peripheral nervous system neoplasm	7.89e-05	0.00155	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	7.76e-05	0.00152	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	7.62e-05	0.0015	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	7.53e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	7.53e-05	0.00148	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	7.39e-05	0.00145	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	7.36e-05	0.00145	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	7.27e-05	0.00143	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	7.08e-05	0.00139	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.07e-05	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IFNB1—peripheral nervous system neoplasm	6.83e-05	0.00134	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.78e-05	0.00133	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	6.75e-05	0.00133	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.67e-05	0.00131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	6.67e-05	0.00131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	6.6e-05	0.0013	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.55e-05	0.00129	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.46e-05	0.00127	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	6.36e-05	0.00125	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.36e-05	0.00125	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KNG1—peripheral nervous system neoplasm	6.33e-05	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.22e-05	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	6.19e-05	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	6.13e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.09e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	6.09e-05	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.96e-05	0.00117	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.92e-05	0.00116	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GNS—peripheral nervous system neoplasm	5.72e-05	0.00112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	5.66e-05	0.00111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	5.54e-05	0.00109	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	5.48e-05	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	5.48e-05	0.00108	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.38e-05	0.00106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.36e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	5.33e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.32e-05	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	5.28e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	5.27e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.21e-05	0.00102	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ENO2—peripheral nervous system neoplasm	5.18e-05	0.00102	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.18e-05	0.00102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	5.14e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.95e-05	0.000972	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.95e-05	0.000971	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	4.94e-05	0.00097	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.93e-05	0.000968	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.84e-05	0.000949	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.82e-05	0.000946	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.78e-05	0.000938	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.73e-05	0.000929	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.71e-05	0.000925	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.7e-05	0.000923	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.66e-05	0.000914	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.58e-05	0.0009	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.55e-05	0.000894	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.45e-05	0.000873	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—BCHE—peripheral nervous system neoplasm	4.38e-05	0.00086	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.36e-05	0.000857	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.35e-05	0.000854	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	4.31e-05	0.000846	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.23e-05	0.00083	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.18e-05	0.00082	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.14e-05	0.000812	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TH—peripheral nervous system neoplasm	4.12e-05	0.000808	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—HRAS—peripheral nervous system neoplasm	4.08e-05	0.000801	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	4e-05	0.000786	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.91e-05	0.000768	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.9e-05	0.000765	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	3.85e-05	0.000756	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	3.79e-05	0.000745	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.77e-05	0.00074	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.71e-05	0.000729	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.64e-05	0.000714	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.63e-05	0.000712	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.62e-05	0.000711	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	3.61e-05	0.00071	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.6e-05	0.000706	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.5e-05	0.000687	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	3.46e-05	0.00068	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.42e-05	0.000672	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GNAS—peripheral nervous system neoplasm	3.36e-05	0.00066	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.34e-05	0.000656	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.34e-05	0.000656	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ABCB1—peripheral nervous system neoplasm	3.3e-05	0.000648	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.27e-05	0.000642	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.27e-05	0.000641	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.18e-05	0.000624	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.18e-05	0.000624	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.16e-05	0.00062	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.03e-05	0.000595	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.02e-05	0.000594	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.94e-05	0.000577	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	2.93e-05	0.000574	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	2.91e-05	0.000572	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.9e-05	0.00057	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.87e-05	0.000564	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.86e-05	0.000561	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.79e-05	0.000549	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.79e-05	0.000548	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.78e-05	0.000546	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	2.75e-05	0.00054	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.72e-05	0.000535	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.7e-05	0.000531	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.66e-05	0.000523	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.51e-05	0.000493	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.5e-05	0.00049	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.44e-05	0.00048	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.38e-05	0.000467	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	2.31e-05	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.31e-05	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	2.25e-05	0.000441	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.21e-05	0.000434	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	2.2e-05	0.000433	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.2e-05	0.000432	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.15e-05	0.000422	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.05e-05	0.000402	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.02e-05	0.000397	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.97e-05	0.000386	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.93e-05	0.000379	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.91e-05	0.000375	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.88e-05	0.000369	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	1.77e-05	0.000348	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.77e-05	0.000347	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.74e-05	0.000341	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.73e-05	0.000339	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.000333	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	1.69e-05	0.000332	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.62e-05	0.000317	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.54e-05	0.000303	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.53e-05	0.0003	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.52e-05	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	1.5e-05	0.000294	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.44e-05	0.000282	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.43e-05	0.000281	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.4e-05	0.000276	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.4e-05	0.000274	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.39e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.37e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000264	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.33e-05	0.000261	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.3e-05	0.000256	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.29e-05	0.000254	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.27e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.26e-05	0.000248	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.26e-05	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.25e-05	0.000244	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.24e-05	0.000243	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.23e-05	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.22e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.22e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.16e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.14e-05	0.000224	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.12e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.11e-05	0.000218	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.08e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.05e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.04e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.03e-05	0.000203	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.02e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.02e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.01e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.72e-06	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.72e-06	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.51e-06	0.000187	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.45e-06	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.36e-06	0.000184	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	9.23e-06	0.000181	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—peripheral nervous system neoplasm	9.07e-06	0.000178	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.88e-06	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.58e-06	0.000168	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.49e-06	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.44e-06	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.98e-06	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.87e-06	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.85e-06	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.81e-06	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.64e-06	0.00015	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.5e-06	0.000147	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.47e-06	0.000147	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.31e-06	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.74e-06	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.6e-06	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.46e-06	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.18e-06	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	6.06e-06	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	6e-06	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.74e-06	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.45e-06	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.07e-06	9.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.35e-06	6.57e-05	CbGpPWpGaD
